恶性肿瘤患者血流感染病原分析及血糖检测的临床意义

陈祝俊, 丁志敏, 马晓路, 王砚春, 胡昊昀, 卢仁泉, 郭林

  1. 1.复旦大学附属肿瘤医院检验科,复旦大学上海医学院肿瘤学系,上海 200032
    2.上海中医药大学附属曙光医院检验科,上海 201203
  • 收稿日期:2023-07-03 修回日期:2023-09-06 出版日期:2023-10-30 发布日期:2023-10-31
  • 通信作者: 郭林
  • 作者简介:陈祝俊 (ORCID:0009-0003-3159-8068),主管技师。

摘要/Abstract

摘要:

背景与目的: 恶性肿瘤患者合并血流感染(bloodstream infection,BSI)的发病率逐渐增高,其治疗结果与感染病原密切相关,同时血糖对该类患者病情发生、发展亦有重要影响。本研究旨在分析恶性肿瘤患者合并BSI时的病原菌分布特征,并探讨合并BSI时血糖检测的临床意义、变化趋势及其对患者的预后价值。方法: 回顾性分析2019年10月—2022年12月在复旦大学附属肿瘤医院诊治的434例患恶性肿瘤合并BSI及同时期409例患恶性肿瘤未并发BSI患者的临床特征,统计患者合并BSI病原菌情况、空腹血糖、降钙素原(procalcitonin,PCT)等指标,并收集患者的随访信息。采用SPSS 26.0、Graphpad等软件进行数据分析。结果: 恶性肿瘤合并BSI最常见病原菌前3位是大肠埃希菌(29.4%)、肺炎克雷伯菌(13.8%)、铜绿假单胞菌(4.8%)。8.5%的患者存在两种及以上病原菌混合感染。最终与致死有关菌株100株,大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌仍列前3位,分别占21.0%、12.0%和10.0%。生存分析显示两种及以上病原菌混合感染与单一感染相比预后较差(P = 0.000)。恶性肿瘤合并BSI患者症状初期空腹血糖水平(中位数为7.39 mmol/ L,四分位区间为5.95 ~ 9.88 mmol/L)显著高于未发生BSI患者(中位数为5.97 mmol/L,四分位区间为5.25 ~ 7.06 mmol/L,P = 0.000)。疾病初期空腹血糖水平判定患者发生BSI的受试者工作特征(receiver operating characteristic,ROC)曲线的曲线下面积(area under the curve,AUC)为0.718,高于经典诊断标志物PCT(AUC = 0.708);两者联合可进一步提高诊断效能(AUC = 0.761)。生存分析结果显示,BSI初期空腹血糖水平较高的患者预后较差(HR = 3.067,95% CI:1.375 ~ 6.838,P = 0.000)。此外,BSI初期空腹血糖变化程度越大,患者死亡风险越高(HR = 2.150,95% CI:1.125 ~ 4.109,P <0.01)。结论: 临床怀疑BSI患者应结合病原菌分布使用抗生素,并监测血糖水平以早期了解感染情况,采取干预措施,使患者获益。

关键词: 恶性肿瘤, 血流感染, 血清葡萄糖, 病原分布特点

Abstract:

Background and purpose: The incidence rate of bloodstream infection (BSI) in patients with malignant tumor increases gradually with the progress of anti-tumor treatment. The treatment outcome is closely related to the infection of pathogen. At the same time, blood glucose also has a significant impact on the occurrence and development of the disease in this type of patients. This research aimed to retrospectively analyze the distribution characteristics of infectious pathogens isolated in patients with malignant tumors combined with bloodstream infection, the significance of serum glucose detection and prognostic value of its variation trend. Methods: Data of 434 malignant tumor patients with BSI and 409 patients without BSI treated in Fudan University Shanghai Cancer Center were retrospectively analyzed in this research. We utilized SPSS 26.0, Graphpad, Medcalc and Office software etc. to statistically analyze all the data covering clinical characteristics, infectious pathogens and biochemical parameters which were collected from Oct. 2019 to Dec. 2022. Results: The top three isolates in malignant tumor patients with BSI were Escherichia coli (29.4%), Klebsiella pneumoniae (13.8%) and Pseudomonas aeruginosa (4.8%). There were two or more mixed pathogenic bacteria in 8.5% patients. There were totally 100 deadly strains, among which the top three isolates were Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, accounting for 21.0%, 12.0% and 10.0% of the diseases, respectively. Survival analysis showed that mixed infection had a poorer prognosis compared to single infection (P=0.000). The fasting blood glucose level at the initial stage of symptoms was significantly higher in malignant tumor patients with BSI (median 7.39 mmol/L, interquartile range 5.95-9.88 mmol/L) than in tumor patients without BSI (median 5.97 mmol/L, interquartile range 5.25-7.06 mmol/L, P=0.000). The area under curve (AUC) of the receiver operating characteristic (ROC) curve of the patients with BSI determined by the fasting glucose level at the beginning of the disease was 0.718, which was higher compared with procalcitonin (PCT), the classic diagnostic marker (AUC=0.708). The combination of these two parameters could even improve diagnostic efficiency (AUC=0.761). Furthermore, survival analysis showed that the prognosis of patients with high level of fasting glucose at the beginning of BSI was poor (HR=3.067, 95% CI: 1.375-6.838, P=0.000). In addition, the greater the glycemic variability at the beginning of BSI, the higher the risk of death was shown (HR=2.150, 95% CI: 1.125-4.109, P<0.01). Conclusion: It is suggested that patients with clinically suspected BSI should use antibiotics based on the distribution of isolates, and glucose levels should be monitored to access the infection early so as to take timely intervention and obtain greater treatment benefits.

Key words: Malignant tumors, Blood stream infection, Serum glucose, Distribution characteristics of infectious pathogens

中图分类号: 

相关文章

[1] 杨梓怡, 顾丙新, 许晓平, 宋少莉. 18F-FDG和68Ga-FAPI PET/CT在不同恶性肿瘤肺转移诊断中的对比研究[J]. 中国癌症杂志, 2023, 33(9): 829-833.
[2] 孙崇源, 赵东兵. 循环肿瘤DNA在胃癌诊疗中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 782-789.
[3] 中国临床肿瘤学会免疫治疗专家委员会, 上海市抗癌协会肿瘤生物治疗专业委员会. 基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识(2022年版)[J]. 中国癌症杂志, 2023, 33(5): 527-548.
[4] 中国抗癌协会肿瘤内分泌专业委员会. 妇科恶性肿瘤免疫治疗中国专家共识(2023年版)[J]. 中国癌症杂志, 2023, 33(10): 954-967.
[5] 胡夕春, 胡志皇, 王碧芸, 王佳蕾, 陶荣, 张剑, 郭伟剑, 陈洁, 罗志国, 李婷, 黄明主, 邱立新, 桑友洲. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
[6] 赵明明, 王天佑, 王超. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022, 32(11): 1098-1104.
[7] 中国抗癌协会肿瘤内分泌专业委员会. 二甲双胍辅助治疗合并2型糖尿病的恶性肿瘤患者的专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(11): 1121-1132.
[8] 中国抗癌协会妇科肿瘤专业委员会. 阴道恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 546-560.
[9] 朱俊军, 葛乃建, 杨业发. 恶性肿瘤植入放射性 125 I粒子出现迁移的研究现状与展望[J]. 中国癌症杂志, 2021, 31(4): 257-262.
[10] 吴春晓, 顾 凯, 庞 怡, 鲍萍萍, 王春芳, 施 亮, 龚杨明, 向詠梅, 窦剑明, 施 燕, 付 晨 . 2016年上海市恶性肿瘤发病和死亡情况与2002—2016年的变化趋势分析[J]. 中国癌症杂志, 2021, 31(10): 879-891.
[11] 冯小双, 周昌明, 莫 淼, 袁 晶, 沈 洁, 王泽洲, 张志红, 秦一雨, 吴 炅, 郑 莹, 郭小毛 . 以大型单中心医院登记为基础的2万例癌症转移患者的转移特征及生存分析[J]. 中国癌症杂志, 2021, 31(1): 11-19.
[12] 周昌明, 莫 淼, 袁 晶, 沈 洁, 王泽洲, 张志红, 朱 骥, 秦一雨, 郑 莹, 吴 炅, 郭小毛 . 以医院登记为基础的20万例恶性肿瘤患者生存报告[J]. 中国癌症杂志, 2020, 30(1): 11-24.
[13] 尹翼鹏晨,张 琴,傅小龙. 纳米材料在肿瘤诊疗中的应用研究进展[J]. 中国癌症杂志, 2019, 29(5): 328-337.
[14] 赵雨笛, 谭 芳,严志凌,李盈甫,戴书颖,周紫云,张新文,刘舒媛,史 荔,姚宇峰. CD44基因多态性与宫颈癌及非小细胞肺癌的相关性[J]. 中国癌症杂志, 2019, 29(4): 277-283.
[15] 鲍萍萍,吴春晓,张敏璐,彭 鹏,王春芳,龚杨明,顾 凯,向詠梅, 施 亮,. 2015年上海市恶性肿瘤流行特征分析[J]. 中国癌症杂志, 2019, 29(2): 81-99.